The purpose of this study is to evalue the effects of nicotinamide adenine dinucleotide (NAD) supplementation (nicotinamide riboside (NR) form) on sleep in healthy adults compared to a placebo. NAD is important for brain health and energy balance and a proposed explanation for its effect on sleep is that NAD supplementation restores the neurophysiological capacity of the brain to 'rest' during sleep. If this is the case, we expect the administration to result in improvements in sleep quality (and most likely sleep quantity) compared to placebo. Participants will receive either NAD supplementation or a placebo and their sleep will be measured to detect any differences between the two groups.
Participant must be 40 to 60 years of age inclusive, at the time of signing the informed consent.
Male or female.
Participants who are healthy as determined by medical evaluation including medical history and physical examination.
Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the study protocol.
History of sleep disorders (e.g. insomnia, sleep apnea).
Abnormal findings on PSG, such as sleep related breathing disorders (apnea-hypopnea index (AHI) ≥ 5), sleep related movement disorders (periodic limb movement index (PLMI) ≥ 15, and parasomnias (like REM sleep behavior disorder (RBD)).
Chronic use of alcohol, tobacco, or medications affecting sleep.
Significant psychiatric or medical conditions (including neurological, heart, lung, or sleep disorders/diseases).
Haukeland University Hospital
Lead sponsor
University of Bergen
Collaborator